

Heidelberg Pharma AG
Ladenburg, Germany
German Securities Identification Number: A11QVV
ISIN: DE000A11QVV0

Invitation to the virtual Annual General Meeting of Heidelberg Pharma AG

We hereby cordially invite our shareholders to the virtual Annual General Meeting of Heidelberg Pharma AG, Ladenburg, Germany, which will take place on Tuesday, 28 June 2022 at 11:00 a.m. (CEST) and due to the continued COVID-19 pandemic will again be held as a virtual Annual General Meeting without the physical presence of the shareholders or their authorized representatives, with the exception of the proxies appointed by the Company.

The venue of the meeting as defined by German Stock Corporation Act is the Company's registered office at Gregor-Mendel-Str. 22, 68526 Ladenburg, Germany. The shareholders and their authorized representatives will have neither the right nor the option to be physically present at the meeting venue. An audio and video broadcast of the entire Annual General Meeting will be available on the Internet for duly registered shareholders or their authorized representatives via the Company's website at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> in the password-protected Internet service. Shareholders – or their authorized representatives – will exercise their right to vote exclusively by means of electronic mail-in ballot or by authorizing and instructing the proxies appointed by the Company.

Agenda

- 1. Presentation of the adopted annual financial statements of Heidelberg Pharma AG and the approved consolidated financial statements and the combined management report for Heidelberg Pharma AG and the Heidelberg Pharma Group, including the explanatory report of the Executive Management Board regarding the disclosures pursuant to Section 289 and Section 315a of the German Commercial Code (Handelsgesetzbuch, HGB) as well as the report of the Supervisory Board – in each case for the 2020/2021 fiscal year ended 30 November 2021**

The documents mentioned in agenda item 1 are available on the Internet at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>.

The Supervisory Board approved the annual financial statements and the consolidated financial statements prepared by the Executive Management Board. Hence there is no need for the Annual General Meeting to adopt a resolution on this agenda item.

2. Resolution on the formal approval of the actions of the members of the Executive Management Board

The Supervisory Board and the Executive Management Board propose formally approving the actions of the members of the Executive Management Board during the 2020/2021 fiscal year ended 30 November 2021.

3. Resolution on the formal approval of the actions of the members of the Supervisory Board

The Executive Management Board and the Supervisory Board propose formally approving the actions of the members of the Supervisory Board during the 2020/2021 fiscal year ended 30 November 2021.

4. Resolution on the appointment of the auditor of the annual financial statements and the consolidated financial statements for the 2021/2022 fiscal year

Following the recommendation of the Supervisory Board's Audit Committee, the Supervisory Board proposes adopting the following resolution:

Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Frankfurt, is elected to serve as the auditor of the annual financial statements and the consolidated financial statements for the 2021/2022 fiscal year ending 30 November 2022.

5. Increase in the number of Supervisory Board members; amendment to the Articles of Association

The Company disclosed in an ad hoc announcement on 27 February 2022 that it had entered into an investment agreement with Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) ("**Huadong**"). In this agreement, the Company committed to implementing a rights issue from Authorized Capital 2020/1 ("**rights issue**") in which specific existing shareholders will waive their pre-emption right and Huadong will acquire new shares in the Company. Once the rights issue has been implemented and shares have been purchased from the existing shareholder dievini Hopp BioTech holding GmbH & Co. KG, Huadong will hold approximately 35% of the Company's shares.

In accordance with Section 95 sentence 3 of the German Stock Corporation Act (Aktiengesetz, AktG), the Annual General Meeting of the Company can elect a Supervisory Board comprising at least three members, though the number does not necessarily have to be divisible by three. Article 10 (1) of the Company's Articles of Association currently sets out that the Supervisory Board shall be comprised of five members. This is to be amended, with the number of Supervisory Board members

being increased to seven to enable Huadong to be represented in the Company's Supervisory Board by two members.

Now, therefore, the Executive Management Board and the Supervisory Board propose adopting the following resolutions:

- a) Article 10 (1) sentence 1 of the Articles of Association shall be revised as follows:

“The Supervisory Board shall be comprised of seven members.”

- b) The Executive Management Board is instructed to register the amendment to the Articles of Association to be resolved under agenda item 5 of this Annual General Meeting for entry in the Commercial Register only after the implementation of the rights issue using Authorized Capital 2020/I has been entered in the Commercial Register.

6. Elections to the Supervisory Board

The Company's Supervisory Board is constituted in accordance with Section 95 and Section 96 (1) AktG as well as Article 10 (1) of the Company's Articles of Association and currently has five members. Given that the Company is not subject to co-determination laws, its Supervisory Board comprises solely shareholder representatives. Unless the Annual General Meeting resolves otherwise, the members of the Supervisory Board are elected in accordance with Article 10 (2) of the Company's Articles of Association for a period ending at the close of the Annual General Meeting that resolves to formally approve the Supervisory Board members' actions for the fourth fiscal year following the commencement of their term of office. The fiscal year in which their term of office commences is not counted.

The existing five members of the Supervisory Board elected by the Annual General Meeting on 22 July 2020 under agenda item 7 have been elected on the same conditions for a period ending at the close of the Annual General Meeting that resolves to formally approve the Supervisory Board members' actions for the fourth fiscal year following the commencement of their term of office. Their term of office is thus expected to last until the close of the Annual General Meeting in 2025.

The Company disclosed in an ad hoc announcement on 27 February 2022 that it had entered into an investment agreement with Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) (“**Huadong**”). In this agreement, the Company committed to implementing a rights issue from Authorized Capital 2020/I (“**rights issue**”) in which specific existing shareholders will waive their pre-emption right and Huadong will acquire new shares in the Company. Once the rights issue has been implemented and shares have been purchased from the existing shareholder dievini Hopp BioTech holding GmbH & Co. KG, Huadong will hold approximately 35% of the Company's shares. To facilitate Huadong's representation

in the Supervisory Board, agenda item 5 of this Annual General Meeting provides for the Supervisory Board to be enlarged to seven members. Under agenda item 5 of this Annual General Meeting, two new members of the Supervisory Board shall therefore be elected. Their term of office shall correspond to the term of office of the existing Supervisory Board members, which means that their term of office is also expected to last until the close of the Annual General Meeting in 2025. Consequently, the two new members of the Supervisory Board are to be elected for a term of office ending at the close of the Annual General Meeting that resolves to formally approve the actions of the Supervisory Board members for the second fiscal year following the commencement of their term of office. In electing the Supervisory Board members, the Annual General Meeting is not bound by nominations. In accordance with Section 95 sentence 3 AktG and for the reasons outlined above, the nomination for the new Supervisory Board members provides for the election of two members, with these members to be elected with effect from the date of the entry in the Commercial Register of the amendment to the Articles of Association to be resolved under agenda item 5.

The Supervisory Board now proposes that the persons named below under a) and b) be elected as Supervisory Board members effective from the entry in the Commercial Register of the amendment to the Articles of Association resolved by the Annual General Meeting on 28 June 2022 under agenda item 5. The individuals named under a) and b) are to be elected for the period ending at the close of the Annual General Meeting that resolves to formally approve the actions of the Supervisory Board members for the second fiscal year following the commencement of their term of office (i.e. probably the 2025 Annual General Meeting). The fiscal year in which their term of office commences is not counted.

a) Brady Yumin Zhao

Occupation: Vice President, China Grand Enterprise, Inc., Beijing, PRC, which is the controlling company of Huadong Medicine Co., Ltd., Hangzhou, China

Place of residence: Chaoyang District, Beijing, PR China

b) Dongzhou Jeffery Liu

Occupation: CSO and President of Huadong Global Development, Huadong Medicine Co., Ltd., Hangzhou, China

Place of residence: Monroe, New York, USA

Positions held:

The proposed candidates are listed under (i) as a member of a statutory Supervisory Board of the specified companies and/or under (ii) as a member of comparable national and foreign control committees of companies:

- a) Brady Xumin Zhao
 - (i) None
 - (ii) None
- b) Dongzhou Jeffery Liu
 - (i) None
 - (ii) None

More information on the nominees can be found on the Company's website below:

<https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>

It is intended to have the Annual General Meeting vote on the nominations individually (separate ballot).

In accordance with the German Corporate Governance Code, the proposed candidates will ensure that they have sufficient time available to discharge their duties; furthermore, the Supervisory Board has satisfied itself that the proposed candidates are able to devote the expected amount of time required.

In the Supervisory Board's estimation, none of the proposed candidates has personal or business relations with Heidelberg Pharma AG or its Group companies or with the executive bodies of Heidelberg Pharma AG that are required to be disclosed in accordance with the German Corporate Governance Code (GCGC). The two candidates work for Huadong, which will hold approximately 35% of the Company's shares after the rights issue has been implemented and shares have been purchased from the existing shareholder dievini Hopp BioTech holding GmbH & Co. KG.

The nomination takes account of the legal requirements and the objectives determined by the Supervisory Board regarding its composition and seeks to fulfill the profile of skills developed by the Supervisory Board for the entire Board. In particular, the Supervisory Board comprising seven members will continue to be made up at least 50% of members who are independent of the Company within the meaning of the German Corporate Governance Code.

The candidates put forward for election are familiar with the sector in which the Company operates.

The Supervisory Board member Dr. Georg F. Baur has expertise in the field of auditing. The Supervisory Board member Dr. Mathias Hothum has expertise in the field of accounting.

7. Resolution on revocation of Authorized Capital 2020/I and creation of new Authorized Capital 2022/I with the option to disapply statutory pre-emption rights; amendment to the Articles of Association

The Company disclosed in an ad hoc announcement on 27 February 2022 that it had entered into an investment agreement with Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) (“**Huadong**”). In this agreement, the Company committed to implementing a rights issue from Authorized Capital 2020/I (“**rights issue**”) in which specific existing shareholders will waive their pre-emption right and Huadong will acquire new shares in the Company. Once the rights issue has been implemented and shares have been purchased from the existing shareholder dievini Hopp BioTech holding GmbH & Co. KG, Huadong will hold approximately 35% of the Company’s shares. The investment agreement is subject to a variety of conditions for completion that must be fulfilled by 27 August 2022 (long stop date). If the conditions for completion are not fulfilled by 27 July 2022, Huadong is authorized to extend the long stop date until 27 October 2022.

The Company has Authorized Capital 2020/I in accordance with Article 5 (8) of its Articles of Association that was created by resolution of the Annual General Meeting on 22 July 2020 under agenda item 5 and exists in the amount of EUR 12,408,649.00. Authorized Capital 2020/I is to be utilized in full in connection with the rights issue. To continue to give the Executive Management Board suitable latitude, also in case the rights issue cannot be implemented, the existing Authorized Capital 2020/I shall be canceled if the Authorized Capital is not exercised by 27 October 2022 and new Authorized Capital 2022/I created that authorizes an increase of up to approx. 45% of the Company’s share capital with, under certain conditions, disapplication of shareholders’ pre-emption rights in the amount of up to 10% of the share capital. The revocation of Authorized Capital 2020/I shall be effective only if Authorized Capital 2022/I takes its place to legal effect. If Authorized Capital 2020/I is to be utilized in full for the rights issue, new Authorized Capital 2022/I shall also be created in the scope described above.

The Executive Management Board and Supervisory Board therefore propose that the following be adopted:

- a) Revocation of Authorized Capital 2020/I; amendment to the Articles of Association

To the extent that this authorization has not been utilized when Authorized Capital 2022/I resolved in accordance with b) and c) is recorded in the Commercial Register, Authorized Capital 2020/I pursuant to Article 5 (8) of the Articles of Association shall be revoked as of the date on which Authorized Capital 2022/I resolved in accordance with b) and c) is recorded in the Commercial Register.

b) Creation of new Authorized Capital 2022/I

The Executive Management Board shall be authorized, with the approval of the Supervisory Board, to increase the Company's share capital by up to a total of EUR 20,992,229.00 by issuing up to 20,992,229 new no par value bearer shares in return for cash contributions and/or contributions in kind on one or several occasions up to (and including) 27 June 2027 (Authorized Capital 2022/I). The shareholders generally have a pre-emption right in connection with capital increases. The shares may also be acquired by one or more banks, subject to the obligation to offer them to the shareholders for subscription. However, the Executive Management Board is authorized, subject to the approval of the Supervisory Board, to disapply shareholders' pre-emption rights:

- aa) in the event of a cash capital increase, where this is necessary to avoid fractional shares; or
- bb) in the event of a capital increase against contributions in kind; or
- cc) in the event of a cash capital increase, where the new shares are issued on a foreign stock exchange in connection with an IPO.

The total number of shares issued on the basis of the above authorizations, with pre-emption rights being disappplied for capital increases against contributions in cash and/or in kind, including the setoffs listed below, must not exceed 10% of the share capital – calculated on the date on which the authorizations take effect or the date on which the authorizations are exercised, whichever amount is lower. The above-mentioned 10% limit shall include (i) treasury shares sold after the effective period of these authorizations under disapplication of shareholders' pre-emption rights, (ii) shares issued on the basis of other authorized capital under disapplication of pre-emption rights during the effective period of these authorizations, and (iii) shares to be issued to service convertible bonds and/or bonds with warrants, insofar as the convertible bonds and/or bonds with warrants have been issued during the effective period of these authorizations under disapplication of shareholders' pre-emption rights, but in respect of (i), (ii) and/or (iii) only insofar as the shares are not used to fulfill claims of members of corporate bodies and/or employees of the Company and/or its affiliated companies under employee stock option plans. The maximum level reduced in accordance with the above sentences of this paragraph shall be increased again up to the maximum amount of the new authorization when a new authorization to disapply shareholders' pre-emption rights resolved by the Annual General Meeting after the reduction takes effect, but by no more than 10% of the share capital in accordance with the requirements of sentence 1 of this paragraph.

The Executive Management Board shall be authorized, with the approval of the Supervisory Board, to determine the further details of the capital increase and its implementation.

c) Amendment to the Articles of Association

Article 5 (8) of the Articles of Association is revised as follows:

„(8) *The Executive Management Board is authorized, with the approval of the Supervisory Board, to increase the Company’s share capital by up to a total of EUR 20,992,229.00 by issuing up to 20,992,229 new no par value bearer shares in return for cash contributions and/or contributions in kind on one or several occasions up to (and including) 27 June 2027 (Authorized Capital 2022/I). The shareholders generally have a pre-emption right in connection with capital increases. The shares may also be acquired by one or more banks, subject to the obligation to offer them to the shareholders for subscription. However, the Executive Management Board is authorized, subject to the approval of the Supervisory Board, to disapply shareholders’ pre-emption rights:*

- aa) in the event of a cash capital increase, where this is necessary to avoid fractional shares; or*
- bb) in the event of a capital increase against contributions in kind; or*
- cc) in the event of a cash capital increase, where the new shares are issued on a foreign stock exchange in connection with an IPO.*

The total number of shares issued on the basis of the above authorizations, with pre-emption rights being disappplied for capital increases against contributions in cash and/or in kind, including the setoffs listed below, must not exceed 10% of the share capital – calculated on the date on which the authorizations take effect or the date on which the authorizations are exercised, whichever amount is lower. The above-mentioned 10% limit shall include (i) treasury shares sold after the effective period of these authorizations under disapplication of shareholders’ pre-emption rights, (ii) shares issued on the basis of other authorized capital under disapplication of pre-emption rights during the effective period of these authorizations, and (iii) shares to be issued to service convertible bonds and/or bonds with warrants, insofar as the convertible bonds and/or bonds with warrants have been issued during the effective period of these authorizations under disapplication of shareholders’ pre-emption rights, but in respect of (i), (ii) and/or (iii) only insofar as the shares are not used to fulfill claims of members of corporate bodies and/or employees of the Company and/or its affiliated companies under employee stock option plans. The maximum level reduced in accordance with the above sentences of this paragraph shall be increased again up to the maximum amount of the new

authorization when a new authorization to disapply shareholders' pre-emption rights resolved by the Annual General Meeting after the reduction takes effect, but by no more than 10% of the share capital in accordance with the requirements of sentence 1 of this paragraph.

The Executive Management Board is authorized, with the approval of the Supervisory Board, to determine the further details of the capital increase and its implementation."

- d) The Executive Management Board is instructed to register the amendment to the Articles of Association to be resolved under agenda item 7 of this Annual General Meeting for entry in the Commercial Register only on 27 October 2022 provided the implementation of the rights issue using Authorized Capital 2020/I has not been entered in the Commercial Register prior to this date. If the implementation of the rights issue is entered in the Commercial Register before 27 October 2022, the Executive Management Board of the Company shall be instructed to register the amendment to the Articles of Association to be resolved under agenda item 7 of this Annual General Meeting for entry in the Commercial Register as soon as the implementation of the rights issue has been entered in the Commercial Register.

8. Resolution on creation of new Authorized Capital 2022/II for issuance of shares to employees, members of the Executive Management Board, and advisors with equivalent status under disapplication of shareholders' pre-emption rights and on a corresponding amendment to the Articles of Association

Motivated employees and Executive Management Board members are one of the keys to an enterprise's success. In the past, the Company mainly used stock options, which confer the right to subscribe for shares, as a means of motivating its employees and members of its Executive Management Board. Experience has shown that despite the many positive aspects, these stock option plans also have disadvantages for employees and Executive Management Board members that reduce the desired motivational effect. These disadvantages can be at least partially removed if the Company gives its employees and Executive Management Board members the opportunity to acquire shares directly (participation shares) granting a discount on the purchase price if the shares are held for a certain length of time. They thus give employees and Executive Management Board members an incentive to boost the Company's stock price – and, with it, the enterprise value – in the long term. This medium- to long-term remuneration component thus serves to attract high-performing employees and encourages them to remain with the Company. This is in the interests not only of the employees and Executive Management Board members, but also, as mentioned above, the shareholders and the Company. This

stock option plan shall also include some of the Company's advisors, who are not formal members of the Executive Management Board, but whose activities and scope of duties are largely equivalent to those of an Executive Management Board member. The Supervisory Board shall be appropriately involved in the preparation of the stock option plans and, in accordance with the statutory requirements, shall decide – particularly in the case of the stock option plan for the members of the Executive Management Board – on the features of the stock option plan and the granting of the participation shares, including the relevant terms and conditions.

New Authorized Capital 2022/II is to be created to enable the Company to issue participation shares. The nominal value of the new Authorized Capital 2022/II shall amount to EUR 2,300,000.00 so that the stock option plans can be serviced with new shares throughout the authorization period. Authorized Capital 2022/II shall only be registered and entered in the Commercial Register after the planned rights issue from Authorized Capital 2020/I has been entered in the Commercial Register and has thus become effective. Then, Authorized Capital 2022/II will make up almost 5% of the Company's existing share capital. Together with Authorized Capital 2022/I, Authorized Capital 2022/II will account for 50% of the Company's existing share capital.

The Executive Management Board and the Supervisory Board thus propose adopting the following resolution:

1. The Executive Management Board shall be authorized to increase the Company's share capital, with the approval of the Supervisory Board, by up to a total of EUR 2,300,000.00 by issuing up to 2,300,000 new no par value bearer shares in return for cash contributions on one or several occasions up to (and including) 27 June 2027 (Authorized Capital 2022/II).

The new shares will be offered exclusively to employees of the Company and its affiliated companies, members of the Company's Executive Management Board, and advisors of the Company who are largely equivalent to members of the Executive Management Board. The new shares may also be acquired by one or more banks, subject to the obligation to offer them to employees of the Company and its affiliated companies, members of the Company's Executive Management Board, and advisors of the Company who are largely equivalent to members of the Executive Management Board. Shareholders' pre-emption rights will be disapplied.

The Executive Management Board shall be authorized, with the approval of the Supervisory Board, to determine further details of the utilization of Authorized Capital 2022/II, particularly the conditions governing the issuance of the new no par value shares, the issue price, and the additional rights attached to the shares, as well as the implementation of capital increases.

The Supervisory Board shall be authorized to amend the wording of the Articles of Association to reflect the scope of the capital increase from Authorized Capital 2022/II or after expiration of the authorization period. Insofar as the Supervisory Board represents the Company pursuant to Section 112 AktG, the Supervisory Board is authorized accordingly under Authorized Capital 2022/II.

2. Article 5 of the Articles of Association shall be expanded by adding the following new paragraph (10):

“The Executive Management Board is authorized to increase the Company’s share capital, with the approval of the Supervisory Board, by up to a total of EUR 2,300,000.00 by issuing up to 2,300,000 new no par value bearer shares in return for cash contributions on one or several occasions up to (and including) 27 June 2027 (Authorized Capital 2022/II). The new shares will be offered exclusively to employees of the Company and its affiliated companies, members of the Company’s Executive Management Board, and advisors of the Company who are largely equivalent to members of the Executive Management Board. The new shares may also be acquired by one or more banks, subject to the obligation to offer them to employees of the Company and its affiliated companies, members of the Company’s Executive Management Board, and advisors of the Company who are largely equivalent to members of the Executive Management Board. Shareholders’ pre-emption rights will be disapplied.

The Executive Management Board is also authorized, with the approval of the Supervisory Board, to determine further details of the utilization of Authorized Capital 2022/II, particularly the conditions governing the issuance of the new no par value shares, the issue price, and the additional rights attached to the shares, as well as the implementation of capital increases.

The Supervisory Board is authorized to amend the wording of the Articles of Association to reflect the scope of the capital increase from Authorized Capital 2022/II or after expiration of the authorization period. Insofar as the Supervisory Board represents the Company pursuant to Section 112 AktG, the Supervisory Board is authorized accordingly under Authorized Capital 2022/II.”

3. The Executive Management Board is instructed only to register Authorized Capital 2022/II for entry in the Commercial Register once the rights issue from Authorized Capital 2020/I that is currently underway has been entered in the Commercial Register and has thus become effective.

9. Reduction of Contingent Capital 2011/I; amendment to the Articles of Association

The Company has Contingent Capital 2011/I available, which is included in Article 5 (6) of the Articles of Association. The amount of Contingent Capital 2011/I currently available is EUR 562,637.00. A portion of Contingent Capital 2011/I is now no longer needed and can be reduced to EUR 366,172.00 (the maximum amount still needed to fulfill pre-emption rights). There are no beneficiaries who could stand in the way of the reduction of Contingent Capital 2011/I.

The Executive Management Board and the Supervisory Board thus propose adopting the following resolution:

- a) Conditional Capital 2011/I included in Article 5 (6) of the Articles of Association shall be reduced from EUR 562,637.00 to EUR 366,172.00.
- b) Article 5 (6) sentence 1 of the Company's Articles of Association is revised as follows:

“The Company's share capital is contingently increased by up to EUR 366,172.00 through the issue of up to 366,172 no par value bearer shares (Contingent Capital 2011/I).”

10. Remuneration of members of the Supervisory Board

The Annual General Meeting of the Company resolves on the remuneration of members of the Supervisory Board at least every four years in accordance with Section 113 (3) sentence 1 AktG. The Company's Annual General Meeting last resolved on the remuneration system for the Supervisory Board members on 18 May 2021 under agenda item 8.

In view of the enlargement of the Supervisory Board to seven members provided for under agenda item 6 of this Annual General Meeting, the Executive Management Board and the Supervisory Board propose to increase the maximum amount paid to all Supervisory Board members per fiscal year for committee activities from EUR 39,000.00 to EUR 54,600.00.

The Executive Management Board and Supervisory Board therefore propose that the amended remuneration system for the members of the Supervisory Board described under “Appendix to agenda item 10 – Remuneration system for members of the Supervisory Board” be adopted.

11. Amendment to the Articles of Association relating to the remuneration of members of the Supervisory Board

The change in the remuneration system for the members of the Company's Supervisory Board to be resolved under agenda item 10 and the increase in the maximum amount payable to all members of the Supervisory Board per fiscal year for committee activities from EUR 39,000.00 to EUR 54,600.00 requires an amendment to the Articles of Association. The increase in the limit still needs to be implemented in Article 12 (2) of the Company's Articles of Association.

The Executive Management Board and the Supervisory Board thus propose adopting the following resolution:

Article 12 (2) sentence 4 of the Company's Articles of Association is revised as follows:

“Without limiting the above individual restriction on remuneration for committee activities, the Company shall only grant a maximum amount of EUR 54,600.00 in total per fiscal year in accordance with this paragraph (2) for activities of members of the Supervisory Board in Supervisory Board committees.”

12. Remuneration report

In accordance with the amendment of the German Stock Corporation Act through the German Act Transposing the Second Shareholder Rights Directive (ARUG II), the Executive Management Board and Supervisory Board are required to prepare a remuneration report in accordance with Section 162 AktG and present this to the Annual General Meeting for approval in accordance with Section 120a (4) AktG. The remuneration report was audited by the statutory auditor in accordance with Section 162 (3) AktG to determine whether the disclosures required by law in accordance with Section 162 (1) and (2) AktG were made. The opinion on the audit of this remuneration report is attached to the remuneration report. The Supervisory Board and Executive Management Board propose that the remuneration report for fiscal year 2020/2021 that has been prepared and audited in accordance with Section 162 AktG be approved. The remuneration report is reproduced following the agenda “Appendix to agenda item 12 – remuneration report for fiscal year 2021/2022” and is available on our website at

<https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>

from the time the Annual General Meeting is convened. Furthermore, the remuneration report will also be available there during the Annual General Meeting.

Written report of the Executive Management Board on Agenda Item 7 pursuant to Section 203 (2) sentence 2 and Section 186 (4) sentence 2 of the German Stock Corporation Act on the reasons for authorizing the Executive Management Board to disapply shareholders' pre-emption rights:

1. Existing Authorized Capital 2020/I, reasons for the amendment and report on the utilization of Authorized Capital 2020/I:

Pursuant to Article 5 (5) of the Articles of Association as amended as of the date of publication of this invitation, the Executive Management Board is authorized to increase the Company's share capital, with the approval of the Supervisory Board, by issuing new no par value bearer shares in return for contributions in cash and/or contributions in kind on one or several occasions up to (and including) 21 July 2025 (Authorized Capital 2020/I). Authorized Capital 2020/I was originally resolved by the Annual General Meeting on 22 July 2020 in an amount of EUR 15,515,286.00 and recorded in the Commercial Register on 11 August 2020. At the time of the invitation to the Annual General Meeting to be held on 28 June 2022, Authorized Capital 2020/I has been used once on the basis of a resolution adopted by the Executive Management Board on 15 June 2021 and with the approval of the Supervisory Board given on the same day ("**2021 capital increase**"). The implementation of the 2021 capital increase was recorded in the Commercial Register of the Mannheim Local Court on 17 June 2021. In addition, it is intended that Authorized Capital 2020/I will once again be utilized in full.

As part of the 2021 capital increase, a resolution was adopted to increase the Company's share capital from EUR 31,066,372.00 at that time by EUR 3,106,637.00 to EUR 34,173,009.00 by utilizing Authorized Capital 2020/I in accordance with Article 5 (5) of the Articles of Association by issuing 3,106,637 new ordinary bearer shares with voting rights and having a notional value of EUR 1.00 per share (no par value shares) in return for cash contributions. The pre-emption rights of shareholders were disappplied. New institutional investors specializing in biotechnology were allowed to subscribe, including Polar Capital Biotech Investment Fund and Invus, as well as DH-LT-Investments GmbH, St. Leon-Rot, an investment company owned by Mr. Dietmar Hopp. The subscription price was EUR 6.44. This corporate action generated gross issue proceeds of around EUR 20.0 million. After the implementation of capital increase 2021 was entered in the Commercial Register, only EUR 12,408,649.00 of Authorized Capital 2020/I is now available.

The Company disclosed in an ad hoc announcement on 27 February 2022 that it had entered into an investment agreement with Huadong Medicine Co., Ltd., Hangzhou, China, (SZ 000963; Huadong) ("**Huadong**"). In this agreement, the Company

committed to implementing a rights issue from Authorized Capital 2020/I (“**rights issue**”) in which specific existing shareholders will waive their pre-emption right and Huadong will acquire new shares in the Company.

Authorized Capital 2020/I is to be utilized in full in connection with the rights issue. Up to 12,408,648 shares will therefore be issued at a price of EUR 6.44 per share as part of the rights issue, generating gross proceeds of EUR 80 million.

To continue to give the Executive Management Board suitable latitude, also in case the rights issue cannot be implemented, the existing Authorized Capital 2020/I shall be revoked if the Authorized Capital is not exercised by 27 October 2022 and new Authorized Capital 2022/I shall be created that authorizes the Company’s Executive Management Board to increase the Company’s share capital, with the approval of the Supervisory Board, by up to a total of EUR 20,992,228.00 by issuing up to 20,992,228 new no par value bearer shares in return for contributions in cash or in kind on one or several occasions up to (and including) 27 June 2027.

2. New Authorized Capital 2022/I and the attendant benefits for the Company:

The intention is to create new Authorized Capital 2022/I up to an amount of EUR 20,992,228.00. Authorized Capital 2022/I enables the Executive Management Board to increase the Company’s share capital, with the approval of the Supervisory Board, by up to EUR [20,992,229.00] by issuing new no par value bearer shares in return for contributions in cash and/or in kind on one or several occasions. The Executive Management Board is authorized to disapply shareholders’ statutory pre-emption rights under special circumstances with the approval of the Supervisory Board (see below, item 3). This authorization shall be in effect up to (and including) 27 June 2027.

The proposed authorization regarding the issuing of new shares from Authorized Capital 2022/I is designed to enable the Executive Management Board to react to short-term funding requirements in connection with the implementation of strategic decisions with the Supervisory Board’s approval. A prompt and flexible funding tool is not only necessary, given the current economic situation, it is also in the interest of both the Company and all of its shareholders (e.g. for the purpose of enabling an acquisition and procuring liquidity). The aim is also that the Executive Management Board, with the approval of the Supervisory Board, will continue to be able to procure new capital for the Company at all times and acquire companies, business units, stakes in companies, new technologies, additional products or product candidates in return for shares. Such an anticipatory resolution is customary, both nationally and internationally.

With regard to the amount of the proposed Authorized Capital 2022/I (approx. 45% of the share capital recorded in the Commercial Register), it should be noted that the

Company has the usual capital requirements for a company in its sector and therefore might require substantial authorized capital, among others to finance the further development of the ATAC technology, in particular the clinical development work on the proprietary ATAC candidate HDP-101.

3. Disapplication of shareholders' pre-emption rights:

The proposed resolution provides for an authorization to disapply shareholders' pre-emption rights, which exist in principle when authorized capital is utilized, for certain purposes individually listed in the proposed resolution:

- a) In the case of a capital increase against cash contributions, shareholders' pre-emption rights must be disappplied to avoid fractional amounts. The authorization to disapply shareholders' pre-emption rights for the purpose of using fractional shares is necessary to bring about a viable subscription ratio in a capital increase and thus only serves to use authorized capital in rounded amounts. Fractional shares arise whenever it is impossible to distribute all new shares equally among the shareholders due to either the subscription ratio or the amount of the capital increase. Absent this authorization, carrying out the capital increase would be substantially more difficult these cases. The cost of trading pre-emption rights related to the fractional shares is disproportionate to the advantages for the shareholders. The new shares created by disapplying shareholders' pre-emption rights for fractional shares are not subject to pre-emption rights and may be disposed of in the Company's best interest on the stock market (if possible) or by other means. A dilutive effect, if any, will be minor given the limitation to fractional amounts.
- b) In the case of a capital increase against contributions in kind, shareholders' pre-emption rights must be disappplied to achieve the objectives being pursued with this corporate action. For example, the Company is to be enabled to grow further and strengthen its competitiveness by acquiring companies, stakes in companies, or assets (especially patents and other industrial property rights as well as licenses).

A key element of the Company's corporate strategy is to push ahead with its own development programs and add innovative technologies and new development programs to round out the existing corporate portfolio. This may necessitate forging partnerships, purchasing licenses or acquiring companies. The conclusion of such partnerships, the acquisition of licensing rights and the acquisition of companies that are particularly important for the corporate purpose help to expand the Company's pipeline and technology portfolio, increasing its enterprise value. In the past, this helped to boost the stock exchange price of the Company's shares, benefiting shareholders and

compensating for the disapplication of their pre-emption rights. To be able to pursue this corporate strategy in the future, it makes sense to cancel Authorized Capital 2020/I and create Authorized Capital 2022/I, which extends the time of the former, as proposed (at the same time, however, the option to disapply pre-emption rights in the case of capital increases against contributions in cash and/or in kind in connection with Authorized Capital 2022/I is to be reduced to a total of 10% of the share capital). This will allow stakes in companies and industrial property rights in particular to be acquired in a manner that does not adversely affect the Company's liquidity so that the Company's market position can be further expanded. Financing such an acquisition solely or – if the authorized capital does not suffice – in part with cash is neither possible nor expedient in the case of certain transactions, especially since the sellers or licensors also frequently insist on acquiring shares as consideration, as this can provide economic benefits for them.

The ability to use its shares as acquisition currency gives the Company the leeway it needs to take advantage of any acquisition opportunities that arise, rapidly and flexibly. Disapplying pre-emption rights is necessary in these cases because such acquisitions must be made on short notice and normally cannot be resolved by the Annual General Meeting which convenes just once a year, not to mention that there is no time to convene an extraordinary General Meeting in such situations owing to statutory deadlines. This calls for authorized capital so the Executive Management Board can act quickly with the Supervisory Board's approval.

- c) The ability to disapply pre-emption rights is also intended to facilitate a further issuance of the Company's shares on foreign stock exchanges as market conditions permit and serves the Company's growth. The disapplication of pre-emption rights therefore creates the opportunity for a further listing on a foreign stock exchange. Disapplying pre-emption rights ensures a reasonable placement volume and the best possible utilization of the new shares. In contrast, granting shareholders' pre-emption rights would lead to considerable technical difficulties in placing the new shares and prevent the most advantageous issue price from being achieved. A broader international financing base could better shield the Company against capital market fluctuations and would be more effective in neutralizing local changes in the cost of capital. An international investor structure like this would create greater market liquidity and reduce the Company's dependence on individual investors. In the international biotechnology environment, an additional listing on a foreign stock exchange would also facilitate the acquisition of stakes in other companies through share swaps.

The total number of shares issued on the basis of the above authorizations, under disapplication of pre-emption rights in the case of capital increases against contributions both in cash and in kind, must not exceed 10% of the share capital – calculated on the date on which the authorizations take effect or the date on which the authorizations are exercised, whichever amount is lower. Shares sold or issued or to be issued under disapplication of pre-emption rights in accordance with other authorizations expressly mentioned shall count towards this 10% limit. The above-mentioned 10% limit shall include (i) treasury shares sold after the effective period of these authorizations under disapplication of shareholders' pre-emption rights, (ii) shares issued on the basis of other authorized capital under disapplication of pre-emption rights during the effective period of these authorizations, and (iii) shares to be issued to service convertible bonds and/or bonds with warrants, insofar as the convertible bonds and/or bonds with warrants have been issued during the effective period of these authorizations under disapplication of shareholders' pre-emption rights, but in respect of (i), (ii) and/or (iii) only insofar as the shares are not used to fulfill claims of members of corporate bodies and/or employees of the Company and/or its affiliated companies under employee stock option plans. The maximum level reduced in accordance with the above sentences of this paragraph shall be increased again up to the maximum amount of the new authorization when a new authorization to disapply shareholders' pre-emption rights resolved by the Annual General Meeting after the reduction takes effect, but by no more than 10% of the share capital in accordance with the requirements of sentence 1 of this paragraph.

This capital limit restricts the overall scope of an issue of shares from authorized and contingent capital while disapplying pre-emption rights and also the overall scope of a sale of treasury shares while disapplying pre-emption rights. In this way, shareholders are additionally protected against dilution of their shareholding. However, shares intended for fulfillment of claims of members of the corporate bodies and/or employees of the Company and/or its affiliated companies from employee stock option plans and which are issued while disapplying pre-emption rights are not counted because the dilutive effect for shareholders is low.

The maximum disapplication of pre-emption rights based on Authorized Capital 2022/I comprises 10% of the Company's share capital.

Having weighed all aforementioned circumstances, the Executive Management Board and the Supervisory Board believe that the option to disapply shareholders' pre-emption rights in the aforementioned cases is justified and appropriate, even if it has a dilutive effect for shareholders.

4. Report on the utilization of Authorized Capital 2022/I

The Executive Management Board shall report any utilization of the Authorized Capital 2022/I to the Annual General Meeting.

Written report by the Executive Management Board on agenda item 8 in accordance with Section 203 (1) sentence 1 AktG in conjunction with Section 186 (4) sentence 2 AktG

Under agenda item 8, a proposal will be submitted to the Annual General Meeting to authorize the Executive Management Board, with the approval of the Supervisory Board, to increase the Company's share capital by up to EUR 2,300,000.00 by issuing new no par value bearer shares in return for cash contributions on one or several occasions (Authorized Capital 2022/II). The new Authorized Capital 2022/II shall only be registered for entry in the Commercial Register and then become effective once the rights issue from Authorized Capital 2020/I currently underway has been entered in the Commercial Register and has thus become effective. The authorization is to be granted for the legally permissible length of time of five years, i.e., up until the end of 27 June 2027.

Authorized Capital 2022/II shall serve exclusively to facilitate participation in the Company's share capital ("participation shares") for employees of the Company and its affiliated companies, members of the Company's Executive Management Board, and advisors of the Company who are largely equivalent to members of the Executive Management Board (collectively "beneficiaries"). Along with direct subscription of the participation shares by the beneficiaries, it is also possible to issue the participation shares through banks. The participation shares shall be issued against cash contributions. The issue price shall be determined on the basis of the market price of the shares. In this context, a benefit customary for participation shares can be granted immediately or later through loan structures. Here, due in particular to legal requirements, a distinction can also be made between employees, members of the Executive Management Board and advisors with equivalent status.

The issuance of participation shares is in the interest of both the Company and its shareholders because it fosters identification of the beneficiaries with the Company and the assumption of shared responsibility. Thus, the beneficiaries can participate in the Company's development. It also aligns the Company's interests with those of the beneficiaries.

Through appropriate lock-up or holding periods over several years, the participation shares also allow for arrangements with a long-term incentive effect, in which both positive and negative developments can be taken into account. The participation shares are thus intended to provide an incentive to pay attention to achieving a permanent increase in the enterprise value. In addition, this can strengthen the

beneficiaries' loyalty to the Company, which given the shortage of skilled workers is also in the Company's interest.

In view of the positive effects for companies, the issuance of participation shares to employees in particular is also viewed favorably by lawmakers and facilitated by the law in different ways. Under the provisions of the German Stock Corporation Act, for instance, the required participation shares can be furnished from authorized capital. For this to happen, shareholders' pre-emption rights need to be disapplied. Due to the positive effects described above, the exclusion of pre-emption rights when issuing participation shares is in the interest of the Company and its shareholders and therefore also objectively justified.

Apart from this, the volume of the authorization to issue participation shares in relation to the Company's share capital is kept within narrow limits (approx. 5%), which means that disapplication of pre-emption rights has only a minor effect on shareholders' participation rights. The scope of the authorization to issue participation shares is thus significantly below the statutory maximum of 50% of the share capital existing at the time of the authorization.

The Executive Management Board and the Supervisory Board will carefully examine on a case-by-case basis whether utilization of Authorized Capital 2022/II and the disapplication of shareholders' pre-emption rights are in the interests of the Company and its shareholders. If necessary, the issuance of the participation shares can be tied to further conditions, for example achievement of corporate or individual targets. The Executive Management Board shall report on any utilization of the Authorized Capital 2022/II to the Annual General Meeting.

Appendix to agenda item 10 – Remuneration system for the members of the Supervisory Board

In accordance with the Company's Articles of Association, the members of the Supervisory Board receive a fixed remuneration of EUR 15,000.00 for each full fiscal year of service on the Supervisory Board. The Chairman of the Supervisory Board receives a fixed remuneration of EUR 35,000.00 and the Deputy Chairman receives EUR 25,000.00. Supervisory Board remuneration is paid in four equal installments on the last day of February and on 31 May, 31 August and 30 November of each fiscal year.

Members of a Supervisory Board committee are paid a flat fee of EUR 3,000.00, while chairpersons of such committees are paid EUR 7,000.00 per fiscal year and committee. In each case, remuneration is limited to activities on a maximum of two committees. Over and above this individual limit, the maximum amount paid by Heidelberg Pharma AG for committee activities of all Supervisory Board members combined is capped at EUR 54,600.00 per fiscal year. If this cap is not sufficient to cover all memberships and chairmanships of Supervisory Board committees, it is distributed proportionally among all

committee members and chairpersons in line with the above provisions, unless the Supervisory Board unanimously resolves a different regulation.

An additional allowance is paid for attendance at a maximum of six Supervisory Board meetings in each fiscal year. Meeting chairpersons are paid a flat fee of EUR 3,000.00 and all other members EUR 1,500.00 each per meeting. Supervisory Board members who attend meetings by telephone or virtually receive only half of the allowance. This allowance must be paid with the Supervisory Board member's fixed remuneration. Members of Supervisory Board committees do not receive an attendance allowance for committee meetings.

The remuneration paid to Supervisory Board members who were not in service for a full fiscal year is pro rated in accordance with the duration of their membership on the Supervisory Board.

The Supervisory Board members do not receive variable remuneration, nor are they granted options or similar rights. Supervisory Board members are not entitled to a settlement if their membership ends.

Annex to agenda item 12 - Remuneration report for fiscal year 2021/2022

Remuneration report

Setting the remuneration of the members of the Heidelberg Pharma AG Executive Management Board falls under the purview of a plenary meeting of the Supervisory Board and is reviewed on a regular basis in compliance with the stipulations in Section 87 (1) and (2) and Section 87a of the Stock Corporation Act as well as the recommendations of the German Corporate Governance Code. At the Annual General Meeting held on 18 May 2021, the Executive Management Board and the Supervisory Board presented in item no. 7 of the agenda the current remuneration system of the members of the Executive Management Board, which was approved in accordance with Section 120a (1) of the German Stock Corporation Act.

The remuneration report summarizes the principles used to determine the total remuneration of the Executive Management Board of Heidelberg Pharma AG and explains the structure as well as the remuneration received by the Executive Management Board members. The principles and the amount of remuneration received by the members of the Supervisory Board are also described. The remuneration report follows the recommendations of the GCGC and satisfies the requirements in accordance with the applicable provisions of Section 314 (1) no. 6, Section 315a (2) and Section 289a (2) German Commercial Code including the German Act on Disclosure of Management Board Remuneration (Vorstandsvergütungs-Offenlegungsgesetz).

Remuneration of the Executive Management Board

The Supervisory Board is responsible for determining the remuneration of the Executive Management Board. Remuneration consists of a salary (fixed remuneration), other benefits

(non-cash benefits), a variable remuneration component and a stock option plan with a long-term incentive and risk element.

In the event of the termination of an Executive Management Board member's service for the Company, there is no contractual entitlement to a settlement.

Salary and non-cash benefits

The annual salary of members of the Executive Management Board is determined for the term of office and paid in equal amounts over twelve months. These salaries take into account the financial position of Heidelberg Pharma AG and the level of remuneration paid by competitors.

In addition to his fixed remuneration of EUR 263,000.00, Dr. Schmidt-Brand, whose director's contract was extended until the end of August 2024 effective September 2021, receives the following non-cash benefits: Under the director's contract, Heidelberg Pharma Research GmbH makes payments into a defined-contribution, reinsured pension plan. In 2021, this payment amounted to EUR 11,000.00 (previous year: EUR 11,000.00). As in the previous year, EUR 3,000.00 were paid into a pension fund.

No non-cash benefits within the context of a pension were granted to Professor Pahl in the fiscal year ended in addition to his fixed remuneration of EUR 240,000.00.

In addition, company cars were made available to both members of the Executive Management Board for the entire fiscal year. The value of this non-cash benefit in 2021 was EUR 8,000.00 for Dr. Schmidt-Brand (previous year: EUR 8,000.00) and EUR 13,000.00 (previous year: EUR 13,000.00) for Professor Pahl.

No further benefit obligations exist towards the members of the Executive Management Board.

Variable remuneration

Variable remuneration is contingent upon the achievement of personal targets and Heidelberg Pharma's performance targets. The performance-based remuneration of the members of the Company's Executive Management Board is primarily tied to long-term, sustainable and financial corporate goals of Heidelberg Pharma and refers to the achievement of milestones that are defined at the beginning of each fiscal year. The degree of target achievement and the associated amount of variable remuneration are assessed and determined by the Supervisory Board.

After his director's contract was extended and his remuneration was adjusted during the year, Dr. Schmidt-Brand receives a maximum annual bonus of EUR 110,000.00 (previously EUR 100,000.00). As a result, his maximum annual remuneration comprising fixed and variable remuneration amounts to EUR 373,000.00. In the fiscal year now ended, Dr. Schmidt-Brand was paid a bonus of EUR 71,000.00 for the 2020 fiscal year.

Professor Pahl's annual bonus is capped at EUR 100,000.00. As a result, his maximum annual remuneration comprising fixed and variable remuneration amounts to EUR 340,000.00. In the fiscal year now ended, Professor Pahl was also paid a bonus of EUR 71,000.00 for the 2020 fiscal year.

Remuneration component with incentive and risk features

This remuneration component is based on the 2011, 2017 and 2018 Stock Option Plans which were adopted by the respective Annual General Meetings and can be exercised after four years at the earliest.

This holding period provides a long-term incentive to increase the Company's value. No further requirements beyond the holding period need to be met.

The Supervisory Board grants stock options based on the tasks of the respective member of the Management Board, his/her personal performance, the economic situation, the performance and outlook of the enterprise as well as the common level of the remuneration taking into account the peer companies and the remuneration structure.

In fiscal year 2021, new stock options were issued under the 2018 Stock Option Plan, with 37,000 stock options granted to each member of the Executive Management Board. An amount of EUR 227,000.00 is recognized as a remuneration component representing the grant date fair value, of which EUR 114,000.00 relates to Dr. Schmidt-Brand and EUR 114,000.00 to Professor Pahl.

As of the 30 November 2021 reporting date, the active members of the Executive Management Board held the following options:

| Stock option plan | Maximum issuance to Executive Management Board members | Stock options issued | | |
|-------------------|--|-----------------------|------------------------|----------------|
| | | Dr. Jan Schmidt-Brand | Professor Andreas Pahl | Total |
| 2011 | 346,924 | 222,000 | 90,000 | 312,000 |
| 2017 | 201,200 | 100,600 | 100,600 | 201,200 |
| 2018 | 298,100 | 111,525 | 111,525 | 223,050 |
| Total | 846,224 | 434,125 | 302,125 | 736,250 |

At the reporting date of 30 November 2021, three former members of the Executive Management Board held a total of 25,500 options under the 2011 Stock Option Plan.

Overall, the following fixed and variable remuneration components as well as non-cash benefits and the grant date fair value of pre-emption rights (or the issue of stock options) for Executive Management Board members were recognized as an expense in the 2021 fiscal year:

| Executive Management Board member | Fixed remuneration € | | Variable remuneration ¹ € | | Other remuneration (non-cash benefits) € | | Issuance of stock options € | | Total remuneration ^{1,2} € | |
|------------------------------------|-------------------------|----------------|---|----------------|---|---------------|--------------------------------|----------|--|----------------|
| | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 |
| Dr. Jan Schmidt-Brand ² | 262,500 | 255,000 | 76,875 | 75,000 | 21,395 | 21,395 | 113,590 | 0 | 474,360 | 351,395 |
| Professor Andreas Pahl | 240,000 | 206,667 | 75,000 | 75,000 | 13,276 | 13,276 | 113,590 | 0 | 441,866 | 294,942 |
| Total | 502,500 | 461,667 | 151,875 | 150,000 | 34,670 | 34,670 | 227,180 | 0 | 916,225 | 646,337 |

¹ The exact variable remuneration is usually determined and paid in the following fiscal year. The figures shown here for the 2021 fiscal year are based on provisions that were determined on the basis of assumptions and historical data.

² The remuneration of Dr. Schmidt-Brand refers to his work as Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG and as Managing Director of Heidelberg Pharma Research GmbH. A portion of € 258 thousand (previous year: € 248 thousand) of the total remuneration is attributable to his work as a member of the Executive Management Board of Heidelberg Pharma AG.

The following overview shows the stock options held by members of the Executive Management Board during the year under review and changes in these holdings, as well as the portion of staff costs per beneficiary attributable to these stock options:

| Executive Management Board member | 30 Nov. 2020 Number | Additions Number | Expiry/ return Number | Exercise Number | 30 Nov. 2021 Number |
|-----------------------------------|------------------------|---------------------|-----------------------------|--------------------|------------------------|
| Dr. Jan Schmidt-Brand | 397,125 | 37,000 | 0 | 0 | 434,125 |
| Professor Andreas Pahl | 265,125 | 37,000 | 0 | 0 | 302,125 |
| Total | 662,250 | 74,000 | 0 | 0 | 736,250 |

| Executive Management Board member | Expense in the 2021 IFRS statement of comprehensive income € | Fair value of the options held ¹ € |
|-----------------------------------|--|--|
| Dr. Jan Schmidt-Brand | 87,007 | 734,191 |
| Professor Andreas Pahl | 84,788 | 488,787 |
| Total | 171,795 | 1,222,978 |

¹ As of the respective issue date

As in the previous year, no expense was recognized for former members of the Executive Management Board.

The following figures applied to the previous period:

| Executive Management Board member | 30 Nov. 2019 Number | Additions Number | Expiry/return Number | Exercise Number | 30 Nov. 2020 Number |
|-----------------------------------|---------------------|------------------|----------------------|-----------------|---------------------|
| Dr. Jan Schmidt-Brand | 397,125 | 0 | 0 | 0 | 397,125 |
| Professor Andreas Pahl | 265,125 | 0 | 0 | 0 | 265,125 |
| Total | 662,250 | 0 | 0 | 0 | 662,250 |

| Executive Management Board member | Expense in the 2020 IFRS statement of comprehensive income € | Fair value of the options held ¹ € |
|-----------------------------------|---|--|
| Dr. Jan Schmidt-Brand | 91,400 | 620,601 |
| Professor Andreas Pahl | 76,620 | 375,197 |
| Total | 168,020 | 995,798 |

¹ As of the respective issue date

Remuneration of the Supervisory Board

In accordance with the Company's Articles of Association, the members of the Supervisory Board receive a fixed remuneration of EUR 15,000 for each full fiscal year of service on the Supervisory Board. The Chairman of the Supervisory Board receives a fixed remuneration of EUR 35,000.00 and the Vice Chairmen receive EUR 25,000.00. Supervisory Board remuneration is paid in four equal installments on the last day of February and on 31 May, 31 August and 30 November of each fiscal year.

Members of a Supervisory Board committee are paid a flat fee of EUR 3,000.00, while chairpersons of such committees are paid EUR 7,000.00 per fiscal year and committee. In each case, remuneration is limited to activities on a maximum of two committees. Over and above this individual limit, the maximum amount paid by Heidelberg Pharma AG for committee activities of all Supervisory Board members combined is capped at EUR 39,000.00 per fiscal year. If this cap is not sufficient to cover all memberships and chairmanships of Supervisory Board committees, it is distributed proportionally among all committee members and chairpersons in line with the above provisions, unless the Supervisory Board unanimously resolves a different regulation.

An additional allowance is paid for attendance at a maximum of six Supervisory Board meetings in each fiscal year. Meeting chairpersons are paid a flat fee of EUR 3,000.00 and all other members EUR 1,500.00 each per meeting. Supervisory Board members who

attend meetings by telephone or virtually receive only half of the allowance. This allowance must be paid with the Supervisory Board member's fixed remuneration. Members of Supervisory Board committees do not receive an attendance allowance for committee meetings.

The remuneration paid to Supervisory Board members who were not in service for a full fiscal year is pro rated in accordance with the duration of their membership on the Supervisory Board.

The Supervisory Board members do not receive variable remuneration, nor are they granted options or similar rights. Supervisory Board members are not entitled to a settlement if their membership ends.

In the 2021 fiscal year, the members of the Supervisory Board were paid remuneration of EUR 180,833.00 (previous year: EUR 166,500.00) plus reimbursement of travel expenses.

The table below shows the individual remuneration.

| Supervisory Board member | Fixed remuneration € | | Attendance allowance € | | Committee fee € | | Total remuneration € | |
|---|-------------------------|----------------|---------------------------|---------------|--------------------|---------------|-------------------------|----------------|
| | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 |
| Professor Christof Hettich | 35,000 | 35,000 | 12,000 | 10,500 | 7,000 | 7,000 | 54,000 | 52,500 |
| Dr. Georg F. Baur | 25,000 | 25,000 | 4,500 | 3,750 | 10,000 | 10,000 | 39,500 | 38,750 |
| Dr. Mathias Hothum | 19,583 | 15,000 | 8,250 | 6,750 | 3,000 | 3,000 | 30,833 | 24,750 |
| Dr. Friedrich von Bohlen und Halbach | 15,000 | 15,000 | 6,750 | 3,000 | 7,000 | 7,000 | 28,750 | 25,000 |
| Dr. Birgit Kudlek | 15,000 | 15,000 | 6,750 | 4,500 | 6,000 | 6,000 | 27,750 | 25,500 |
| Total | 109,583 | 105,000 | 47,250 | 28,500 | 33,000 | 33,000 | 180,833 | 166,500 |

The Company's website and the documents and information available there

This invitation to the virtual Annual General Meeting as well as the documents and additional information to be made available to Annual General Meeting participants in connection with the Annual General Meeting can be viewed at the Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> starting from the date of this invitation.

Any shareholder counter-applications, shareholder nominations, and/or amendment proposals from shareholders received by Heidelberg Pharma AG that are required to be made public will likewise be made available at the website stated above. The final voting results will also be published there following the Annual General Meeting.

The website will also allow duly registered shareholders or their authorized representatives, among others, access to the password-protected Internet service for the virtual Annual General Meeting; this service will allow them to exercise their voting rights either by electronic mail-in ballot or while the Annual General Meeting is underway. Duly registered shareholders or their authorized representatives will be able to follow a live audio and video feed of the Annual General Meeting online in its entirety via the password-protected Internet service on 28 June 2022 starting at 11:00 a.m. (CEST) via electronic media (this is not electronic participation).

Total number of shares and voting rights at the time this Annual General Meeting is convened

The Company's share capital of EUR 34,175,809.00 is divided into 34,175,809 no par value bearer shares at the time the Annual General Meeting is convened. Each no par value share grants one vote. Consequently, there are 34,175,809 voting shares at the time the Annual General Meeting is convened. The Company does not hold any treasury shares at the time this Annual General Meeting is convened.

Holding the Annual General Meeting as a virtual Annual General Meeting without the physical presence of the shareholders and their authorized representatives; audio and video feed

In light of the ongoing COVID-19 pandemic, the Annual General Meeting on 28 June 2022 will be held as a virtual Annual General Meeting on the basis of the German Act on Measures in Corporate Law, the Law Governing Cooperatives, Associations, and Foundations, and Residential Property Law to Combat the Effects of the COVID-19 Pandemic dated 27 March 2020 (Federal Gazette I no. 14 2020, p. 570) as amended (hereinafter COVID-19 Act) without the physical presence of the shareholders and their authorized representatives; however, they will be able to participate by joining the meeting via electronic media (**connection**).

Consequently, the shareholders and their authorized representatives (with the exception of the proxies designated by the Company) will not be able to physically attend the Annual General Meeting. However, they will be able to follow the entire Annual General Meeting online via audio and video feed on the Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> via the password-protected Internet service. This audio and video feed will not allow for participation in the Annual General Meeting as within the meaning of Section 118 (1) sentence 2 AktG, or for electronic participation as within the meaning of Section 1 (2) sentence 1, no. 2 (option 2) of the COVID-19 Act. In lieu of the usual admission ticket, duly registered shareholders will be sent unique access information for the password-protected Internet service (“AGM ticket”), which they will be able to use to access the password-protected Internet service made available on the Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>.

Password-protected Internet service for the Annual General Meeting

A password-protected Internet service will be available on Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> starting 7 June 2022 at 00:00 hours (CEST). Following the procedures intended for that purpose, duly registered shareholders (and their authorized representatives, as applicable) will be able to use this area, among other things, to follow the audio and video feed of the Annual General Meeting, to authorize representatives, to submit questions, or have their objections recorded in the minutes. In order to be able to use the password-protected Internet service, they will need to log in using the unique access information that they receive after successfully registering and verifying their shareholdings.

The unique access information required for use of the password-protected Internet service at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> will be sent out once registration is completed prior to the deadline; completed registration includes the Company’s receipt of verification of shareholdings (see the following section “Conditions for participating in the Annual General Meeting and exercising shareholder rights, in particular voting rights”) (“**AGM ticket**”).

Requirements for connecting to the Annual General Meeting and exercising shareholder rights, in particular voting rights

Pursuant to Article 15 (1) of the Articles of Association, those shareholders who register for the Annual General Meeting and provide proof of their shareholdings to the Company (**duly registered shareholders**) have the right to connect to the Annual General Meeting and to exercise their shareholder rights, in particular their voting rights, by means of electronic media. The registration and verification of shareholdings must be received by the Company by no later than the end of the day on

21 June 2022
(24:00 hours CEST)

at the following address, fax number, or e-mail address (e.g., as a scanned file in .pdf format):

Heidelberg Pharma AG
c/o Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Fax: +49 (0)89 / 889 690 633
E-mail: anmeldung@better-orange.de

Verification of shareholdings prepared in text form by the last intermediary in the chain pursuant to Section 67c (3) of the German Stock Corporation Act shall suffice to demonstrate authorization. Such document must confirm share ownership as of the start of the 21st day prior to the Annual General Meeting, i.e., by

7 June 2022
(00:00 hours CEST) (record date)

Better Orange IR & HV AG is the Company's agent authorized to receive both the registrations and the evidence of shareholdings.

Upon timely receipt of the registration, including the verification of shareholdings, the relevant shareholders will be sent their personalized access details for using the password-protected Internet service ("AGM ticket"). We ask shareholders to register and submit their verification of shareholdings to the Company as early as possible.

Significance of the Record Date

The Record Date is the date that governs both the scope and the exercise of a shareholder's right to connect to and vote at the Annual General Meeting. Relative to the Company, a person shall only be considered a shareholder for the purpose of connecting to or exercising the voting right at the Annual General Meeting if they have verified their shareholdings by the Record Date. Persons who do not yet own any shares on the Record Date and only become shareholders after that date are not entitled to connect to the Annual General Meeting or vote, unless they hold a power of attorney or an authorization to exercise a right (see the section below entitled "Authorizing a third party to exercise voting and other rights"). Shareholders who have duly registered and verified their shareholdings may even connect to the Annual General Meeting and exercise their voting right if they sell their shares after the Record Date. The record date is not associated with a ban on selling the shares. The Record Date is not relevant to any right to participate in any dividends.

Exercising voting rights by electronic mail-in ballot

Duly registered shareholders may also cast their votes without participating in the Annual General Meeting by means of electronic communications (**mail-in ballot**).

Mail-in ballots can be submitted, changed or revoked by using the password-protected Internet service accessible at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> following the procedures intended for that purpose.

This option of electronic mail-in voting will be available from 7 June 2022, 0:00 hours (CEST) until the start of voting at the virtual Annual General Meeting on 28 June 2022. The same applies to a revocation or a change of the vote by electronic mail-in ballot.

Exercising voting rights by authorizing and instructing the proxies designated by the Company

The Company offers duly registered shareholders the option of authorizing proxies designated by the Company, who are then obligated to follow the shareholder's instructions.

A form for granting authorizations and issuing instructions will be sent to those shareholders together with the access information for the password-protected Internet service accessible online at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>, and will also be available there for download.

Authorizations with instructions for the Company's designated proxies can be sent, changed or revoked by sending these by

27 June 2022

(24:00 hours CEST, (date of receipt))

to the following address, fax number, or e-mail address:

Heidelberg Pharma AG
c/o Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Fax: +49 (0)89 / 889 690 655
E-mail: hdpharma@better-orange.de

or can be submitted, changed or revoked by using the password-protected Internet service accessible at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> from 7 June 2022, 00:00 hours (CEST) following the procedures intended for that purpose. The date of receipt by the Company will be used to make any relevant determinations.

On the day of the virtual Annual General Meeting, authorizations with instructions for the Company's designated proxies can still be submitted, changed or revoked online until the start of voting via the password-protected Internet service at <https://heidelberg->

pharma.com/en/press-and-investors/annual-general-meeting following the procedures intended for that purpose.

Where the Company's designated proxies have been authorized, instructions absolutely must be issued to them in order for voting rights to be exercised. The proxies are obligated to vote in accordance with their instructions. Without such express instructions, the proxies will not exercise the shareholder's voting rights.

Authorizing a third party to exercise voting and other rights

Shareholders may also have their voting rights and other rights exercised at the Annual General Meeting by duly appointed authorized representatives, e.g., by an intermediary, a shareholders' association, a voting rights advisor, or other individual of their choosing. This method also requires registration and the corresponding proof of ownership of the respective shares prior to the deadline. Appointed third parties can in turn exercise the voting rights by electronic mail-in ballot or by authorizing and instructing the Company's designated proxies (see above). Where the shareholder authorizes more than one individual, pursuant to Section 134 (3) sentence 2 German Stock Corporation Act, the Company may turn away one or more such appointees.

If an authorization is not granted as set out in Section 135 German Stock Corporation Act, the appointment of an authorized representative or revocation of appointment as well as the proof of the appointment for the Company must be declared in "text form" (Section 126b German Civil Code).

A proxy form will be sent to duly registered shareholders together with the access information for the password-protected Internet service accessible online at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>, and will also be available there for download.

Where intermediaries, shareholders' associations, voting rights advisors, or individuals or institutions deemed to have equivalent status as per Section 135 (8) German Stock Corporation Act are appointed as authorized representatives, the specific provisions of Section 135 apply, including the requirement that the authorization be retained in such a way that it can be verified. Consequently, exceptions to the general requirement of "text form" may apply. In certain circumstances, however, the respective appointees may stipulate specific rules for their own authorization. Shareholders are therefore urged to coordinate with the respective appointees in a timely manner, as applicable, regarding the particular form and procedure to be followed for their authorization.

The authorization can be declared directly to the appointee or to the Company. Proof of the authorization can be sent, changed or revoked by sending these by

27 June 2022

(24:00 hours CEST, (date of receipt))

to the following address, fax number, or e-mail address:

Heidelberg Pharma AG
c/o Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Fax: +49 (0)89 / 889 690 655
E-mail: hdpharma@better-orange.de

or can be submitted, changed or revoked by using the password-protected Internet service accessible at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> from 7 June 2022, 00:00 hours (CEST) following the procedures intended for that purpose. The date of receipt by the Company will be used to make any relevant determinations.

On the day of the virtual Annual General Meeting, proxy appointments can only be submitted, changed or revoked by using the password-protected Internet service accessible at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> by following the procedures intended for that purpose.

In order for a proxy to use the password-protected Internet service, the proxy must receive the relevant access details:

Shareholders' right to information pursuant to Section 131 (1) German Stock Corporation Act and Section 1 (2) COVID-19 Act / shareholders' right to ask questions

When a virtual Annual General Meeting is held pursuant to Section 1 (2) COVID-19 Act, the shareholders' right to receive information as set out in Section 131 (1) of the German Stock Corporation Act narrows. Under the COVID-19 Act, the only right available to shareholders is to raise questions via electronic communications (Section 1 (2) sentence 1, no. 3). Additionally, the Executive Management Board may stipulate that questions be submitted no later than one day before the meeting (Section 1 (2) sentence 2 (second half) COVID-19 Act). With the approval of the Supervisory Board, the Heidelberg Pharma AG Executive Management Board has availed itself of this option as follows:

Duly registered shareholders will have the opportunity to ask questions via electronic communications from 7 June 2022, 00:00 hours CEST (see Section 1 (2) sentence 1, no. 3 COVID-19 Act). Questions are to be submitted no later one day before the Annual General Meeting, i.e. no later than

26 June 2022, 24:00 hours CEST

via the password-protected area accessible at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting> by following the procedures intended for that purpose.

Questions submitted after the above-mentioned deadline has passed or submitted in a language other than German will not be considered. As a rule, it is possible for the party raising the question to be identified by name during the question-and-answer period.

The Executive Management Board will decide, at its discretion and in keeping with its obligations under Section 1 (2) sentence 2 (first half) COVID-19 Act, how it will respond to questions.

Having objections recorded in the minutes

From the start of the Annual General Meeting until its end, duly registered shareholders who have exercised their voting rights by electronic mail-in ballot or by granting authorizations can, by means of electronic media, i.e., via the password-protected Internet service accessible at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>, have their objections to proposed Annual General Meeting resolutions recorded in the minutes by the officiating notary by following the procedures intended for that purpose.

Motions to add items to the agenda submitted by a minority pursuant to Section 122 (2) AktG

Shareholders whose total shareholdings are equivalent to 1/20th of the Company's share capital (i.e. 1,708,791 no par value shares) or the notional amount of EUR 500,000.00 (i.e. 500,000 no par value shares) may request to have items placed on the agenda and published. Every request for a new agenda item must be accompanied by an explanation of the reasons therefor or a proposed resolution. The request shall be sent to the Company's Executive Management Board, in writing, and the Company must receive it no later than 30 days before the Annual General Meeting, i.e. no later than by the end of

28 May 2022
(24:00 hours CEST)

at the following address:

The Executive Management Board of Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg
Germany

The submitter of the application must provide evidence of having held the shares for at least 90 days prior to the date of receipt of the application and of holding the shares until a decision is made on the application by the Executive Management Board; Section 70 German Stock Corporation Act is applicable to the calculation of holding period of the shares. The day the application is received is not counted. If a deadline falls on a Saturday, Sunday or holiday, it shall not be advanced to a preceding or postponed to a subsequent business day. Sections 187 to 193 of the German Civil Code shall not be applicable mutatis mutandis.

Any supplements to the agenda that must be published – provided they were not already made public at the time the Annual General Meeting was convened – shall be published in the Federal Gazette immediately after the request has been received and shall also be furnished to such suitable media as may be expected to disseminate the information throughout the European Union. They shall also be published on the Internet and communicated to the shareholders at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>.

**Counter-applications pursuant to Section 126 (1)
and nominations pursuant to Section 127 AktG and Section 1 (2) sentence 3 COVID-
19 Act**

In addition, the Company's shareholders may send counter-applications to proposals of the Executive Management Board and/or the Supervisory Board concerning specific agenda items as well as nominations in connection with the election of Supervisory Board members or auditors. Counter-applications (including any supporting statement), shareholder nominations, and other shareholder requests regarding the Annual General Meeting are to be sent exclusively to the following address:

Heidelberg Pharma AG
c/o Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Fax: +49 (0)89 / 889 690 655
E-mail: antraege@better-orange.de

Counter-applications and nominations that are sent to any other address shall not be considered. Better Orange IR & HV AG has been officially designated to receive counter-applications and nominations on behalf of the Company.

All counter-applications and nominations received up to 14 days prior to the day of the Annual General Meeting, i.e., no later than by the end of the day on

13 June 2022
(24:00 hours CEST)

at the above-stated address, fax number, or e-mail address with proof of share ownership, including the name of the shareholder and any supporting statements to be made available, will be made available online to the other shareholders after their receipt at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>, provided the other conditions underlying the publication requirement under Section 126 German Stock Corporation Act have been met. Statements, if any, by the Company's management will also be posted at the aforementioned Internet address. Only counter-applications and nominations received by the end of the day on 13 June 2022 (24:00 hours CEST) will be deemed duly submitted for purposes of the virtual Annual General Meeting; counter-applications and nominations received after that point will be disregarded.

Aside from the reasons set forth in section 126 (2) of the German Stock Corporation Act, the Executive Management Board also need not make an election proposal available if the proposal does not contain the candidate's name, profession and domicile. Proposals concerning the election of Supervisory Board members need not even be made available if they are not accompanied by information on the proposed candidate's appointments to other statutory supervisory boards as defined in Section 125 (1) sentence 5 of the German Stock Corporation Act.

Counter-applications or nominations for election submitted by shareholders which must be made available pursuant to Section 126 or Section 127 German Stock Corporation Act shall be deemed to have been made at the Annual General Meeting in accordance with Section 1 (2) sentence 3 COVID-19 Act, if the shareholder submitting the application or nomination is duly authorized and has duly registered for the Annual General Meeting.

More information regarding shareholders' rights under Section 122 (2), Section 126 (1), Section 127, and Section 131 (1) German Stock Corporation Act in conjunction with Section 1 (2) COVID-19 Act is available on the Heidelberg Pharma AG website at <https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting>.

Data protection information for shareholders

Heidelberg Pharma AG processes personal information (name, address, e-mail address, number of shares, class of shares, how the shares are held, and number and access data of the AGM ticket; name, address, and e-mail address and number and access data of the AGM ticket of the shareholder representative designated by the respective shareholder, if applicable) on the basis of the applicable data privacy and protection laws so as to allow the shareholders to exercise their rights in connection with the virtual Annual General Meeting, and to comply with the provisions of law concerning an annual general meeting, including the provisions of the COVID-19 Act on holding a virtual annual general meeting.

The processing of personal data of shareholders is absolutely necessary for them to connect to the virtual Annual General Meeting. Heidelberg Pharma AG is the data controller responsible for processing. Article 6 (1) c) of the General Data Protection Regulation (GDPR) is the legal basis for processing the data.

The service providers of Heidelberg Pharma AG that are commissioned for the purpose of organizing the virtual Annual General Meeting (particularly Annual General Meeting, IT, printing and shipping service providers) will receive only personal data from Heidelberg Pharma AG that is necessary for providing the commissioned service and process the data exclusively in accordance with the instructions of Heidelberg Pharma AG. In addition, the shareholders' data may be transmitted to authorities entitled to receive information. Your data will not be transferred to a country outside the EU.

Insofar as shareholders take advantage of the opportunity to submit questions in advance of the virtual Annual General Meeting and their questions are addressed there, they may

be identified by name in this connection. Other participants of the virtual Annual General Meeting may learn this information. This data processing involving the identification of the respective shareholder by name is required in pursuit of our legitimate interests in creating a virtual Annual General Meeting that most closely approximates a physical annual general meeting. The legal basis for this processing is Article 6 (1) (f) GDPR.

As a rule, shareholders' personal data is deleted or anonymized as soon as it is no longer required for the aforementioned purpose and we are no longer obliged to retain it further in accordance with statutory documentation and retention requirements.

Shareholders have the right at any time to require information, the right to require the correction and restriction of data, the right to object to the use of data and the right to require the erasure of data in connection with the processing of your personal data, and a right to data transfer in accordance with Article 15 GDPR. You can exercise these rights vis-à-vis Heidelberg Pharma AG at no cost by sending an e-mail to

datenschutz@hdpharma.com

or by using the following contact information:

Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg, Germany

You also have the right to lodge a complaint with the data protection supervisory authorities pursuant to Art. 77 of the General Data Protection Regulation.

You can contact our company's Data Protection Officer at:

Heidelberg Pharma AG
Data Protection Officer
Gregor-Mendel-Str. 22
68526 Ladenburg, Germany
Fax: +49 6203 1009 19
E-mail: datenschutz@hdpharma.com

More information on data protection is available on the website of Heidelberg Pharma AG at <https://heidelberg-pharma.com/en/privacy-policy>.

Ladenburg, May 2022

Heidelberg Pharma AG
The Executive Management Board

Information pursuant to Section 125 para. 1 German Stock Corporation Act (AktG) in connection with Section 125 para. 5 AktG, Article 4 para. 1 and Table 3 of the Annex to Implementing Regulation (EU) 2018/1212

| Type of Information | Description |
|--|--|
| A. Specification of the message | |
| 1. Unique identifier of the event | HPHA062022HV |
| 2. Type of message | Meeting notice of a General Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: NEWM] |
| B. Specification of the issuer | |
| 1. ISIN | DE000A11QVV0 |
| 2. Name of issuer | Heidelberg Pharma AG |
| C. Specification of the meeting | |
| 1. Date of the General Meeting | 28.06.2022 [format pursuant to Implementing Regulation (EU) 2018/1212: 20220628] |
| 2. Time of the General Meeting | 11:00 hrs. (CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 09:00 UTC] |
| 3. Type of the General Meeting | Ordinary General Meeting [format pursuant to Implementing Regulation (EU) 2018/1212: GMET] |
| 4. Location of the General Meeting | Virtual General Meeting: https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting Within the meaning of the German Stock Corporation Act: Heidelberg Pharma AG, Gregor-Mendel-Str. 22, 68526 Ladenburg, Germany |
| 5. Record Date | 07.06.2022 (00:00 hrs. CEST) [format pursuant to Implementing Regulation (EU) 2018/1212: 20220606] |
| 6. Uniform Resource Locator (URL) | https://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting |